Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company developing various therapeutic candidates that focus on various mental health disorders including depression, substance use disorder, and anxiety. The company's pipeline includes PCN-101, RL-007, DMX-1002, GRX-917, NN-101, VLS-01, EMP-01, RLS-01, DMX-1001, and others. Formerly known as Adripa Holding B.V., Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Name / Ticker | Price | Zen Rating |
---|---|---|
$3.07 | A | |
$8.24 | A | |
$24.29 | A |